Skip to Main Content

Author Details

Alana S Weinstein
University of California San Francisco
1981
24
15
PMIDPaper TitleJournal TitlePublished Year
37289025The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer.Cancer Res2023
36109521Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity.Nat Commun2022
32286548Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer.Prostate Cancer Prostatic Dis2021
32424106Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance.Proc Natl Acad Sci U S A2020
31797609Using Transcriptional Signatures to Find Cancer Drivers with LURE.Pac Symp Biocomput2020
32624423Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer.Urol Oncol2020
32727885Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer.Clin Cancer Res2020
29985747Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.J Clin Oncol2018
29092953TumorMap: Exploring the Molecular Similarities of Cancer Samples in an Interactive Portal.Cancer Res2017
21859563Assessing compliance with national comprehensive cancer network guidelines for elderly patients with stage III colon cancer: the Fox Chase Cancer Center Partners' initiative.Clin Colorectal Cancer2011
17977500Development and implementation of a medical oncology quality improvement tool for a regional community oncology network: the Fox Chase Cancer Center Partners initiative.J Natl Compr Canc Netw2007
11445480Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer.Urology2001
8608540Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02.Cancer1996
8380567Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302.Int J Radiat Oncol Biol Phys1993
8487050Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: a report of Radiation Therapy Oncology Group 83-02.J Clin Oncol1993
8478956Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.J Natl Cancer Inst1993
1451073A randomized trial of accelerated hyperfractionated radiation therapy and bis-chloroethyl nitrosourea for malignant glioma. A preliminary report of Radiation Therapy Oncology Group 83-02.Cancer1992
1583555Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials.J Neurooncol1992
3524837Pulmonary toxicity of carmustine in patients treated for malignant glioma.Cancer Treat Rep1986
3531110A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study.Int J Radiat Oncol Biol Phys1986
6347995A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery; preliminary results of an RTOG study.Int J Radiat Oncol Biol Phys1983
6349785Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study.Cancer1983
6874372Characterization and properties of Hb York (beta 146 His leads to Pro).Hemoglobin1983
7263341Misonidazole and radiotherapy to treat malignant glioma: a phase II trial of the radiation therapy oncology group.Int J Radiat Oncol Biol Phys1981
  • 1 - 24 of 24

Recommended Authors

Michelle Alonso-Basanta
Perelman School of Medicine, University of Pennsylvania
Career Start Year 2000
Number of shared co-authors 0
Wendy Seiferheld
Career Start Year 1999
Number of shared co-authors 4
Helen A Shih
Massachusetts General Hospital and Harvard Medical School
Career Start Year 1997
Number of shared co-authors 0
Ranjit S Bindra
Yale University School of Medicine
Career Start Year 1997
Number of shared co-authors 0
Vinay K Puduvalli
The University of Texas MD Anderson Cancer Center
Career Start Year 1996
Number of shared co-authors 0
Katherine S Panageas
Memorial Sloan Kettering Cancer Center
Career Start Year 1996
Number of shared co-authors 0
Warren P Mason
Princess Margaret Cancer Centre
Career Start Year 1996
Number of shared co-authors 0
Erik P Sulman
NYU Grossman School of Medicine
Career Start Year 1995
Number of shared co-authors 4
John H Suh
Taussig Cancer Institute, Cleveland Clinic
Career Start Year 1994
Number of shared co-authors 1
Kevin Camphausen
National Cancer Institute
Career Start Year 1994
Number of shared co-authors 0
Melania Pintilie
Princess Margaret Cancer Centre, University Health Network
Career Start Year 1993
Number of shared co-authors 1
David M Peereboom
Brain Tumor & Neuro-Oncology Cleveland Clinic Main Campus
Career Start Year 1993
Number of shared co-authors 1
Paul Mitchell
Olivia Newton-John Cancer Research Institute
Career Start Year 1993
Number of shared co-authors 0
Vera J Suman
Mayo Clinic
Career Start Year 1992
Number of shared co-authors 2
Karin Dieckmann
Medical University of Vienna
Career Start Year 1991
Number of shared co-authors 0
Howard A Fine
Meyer Cancer Center
Career Start Year 1990
Number of shared co-authors 3
Roger Stupp
Northwestern University
Career Start Year 1990
Number of shared co-authors 0
Howard Colman
Huntsman Cancer Institute, University of Utah
Career Start Year 1990
Number of shared co-authors 5
Morris D Groves
The University of Texas MD Anderson Cancer Center
Career Start Year 1989
Number of shared co-authors 0
Michael D Prados
University of California san francisco
Career Start Year 1987
Number of shared co-authors 2
Camilo E Fadul
University of Virginia Health System
Career Start Year 1987
Number of shared co-authors 0
Christine Marosi
Medical University of Vienna
Career Start Year 1987
Number of shared co-authors 0
Michael A Vogelbaum
Moffit Cancer Center
Career Start Year 1986
Number of shared co-authors 0
Kenneth R Hess
The University of Texas MD Anderson Cancer Center
Career Start Year 1986
Number of shared co-authors 7
Seth M Steinberg
Center for Cancer Research, National Cancer Institute
Career Start Year 1984
Number of shared co-authors 1
Helen J Ross
Mayo Clinic
Career Start Year 1982
Number of shared co-authors 0
John P Kirkpatrick
Duke University Medical Center
Career Start Year 1978
Number of shared co-authors 0
Wai-Kwan Alfred Yung
University of Texas M.D. Anderson Cancer Center
Career Start Year 1974
Number of shared co-authors 5
J. Martin Brown
Stanford University School of Medicine
Career Start Year 1968
Number of shared co-authors 0
David Schiff
University of Virginia School of Medicine
Career Start Year 1966
Number of shared co-authors 0

Collaborators

Joshua M Stuart
University of California at Santa Cruz
Co-authored papers 8
Eric J Small
University of California san francisco
Co-authored papers 7
Rahul Aggarwal
University of California San Francisco
Co-authored papers 7
Adam Foye
University of California San Francisco
Co-authored papers 7
Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers 7
Matthew B Rettig
David Geffen School of Medicine, University of California los angeles
Co-authored papers 6
Joshi J Alumkal
Rogel Cancer Center, University of Michigan ann arbor
Co-authored papers 6
Jiaoti Huang
Duke University School of Medicine
Co-authored papers 6
Tomasz M Beer
OHSU Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 6
Martin E Gleave
University of British Columbia
Co-authored papers 6
Primo N Lara
University of California Davis Comprehensive Cancer Center
Co-authored papers 5
Christopher P Evans
University of California Davis
Co-authored papers 5
David A Quigley
University of California-San Francisco
Co-authored papers 5
Robert E Reiter
David Geffen School of Medicine at university of california los angeles
Co-authored papers 4
Christopher K Wong
University of California
Co-authored papers 4
George V Thomas
Knight Cancer Institute, Oregon Health and Science University
Co-authored papers 4
Owen N Witte
University of California los angeles
Co-authored papers 4
David A Schoenfeld
Mass General Hospital
Co-authored papers 3
Yulia Newton
University of California, Santa Cruz Genomics Institute
Co-authored papers 2
Joshua Urrutia
Knight Cancer Institute, Oregon Health & Science University (OHSU)
Co-authored papers 2
Eric Lu
David Geffen School of Medicine at university of california los angeles
Co-authored papers 2
Kim N Chi
University of British Columbia
Co-authored papers 2
Vladislav Uzunangelov
University of California
Co-authored papers 2
Thomas J George
UF Health Cancer Center
Co-authored papers 1
Adam M Novak
UC Santa Cruz Genomics Institute, University of California
Co-authored papers 1
Olena Morozova
University of California Santa Cruz Genomics Institute
Co-authored papers 1
Mark A Rubin
University of Bern
Co-authored papers 1
Alexander W Wyatt
University of British Columbia
Co-authored papers 1
Himisha Beltran
Dana-Farber Cancer Institute
Co-authored papers 1
Sahil Chopra
Loma Linda University
Co-authored papers 1
Release 1.2